Now I have a clear picture for calibration. Let me finalize.

**Round 1 Bracket:** 5.5 – 7.5
**Round 2 Narrowing:** Compared against LLaPA (6.00, Reject — PPI prediction with unfair comparison issues) and Bioactivity Prediction (7.00, Accept — benchmark paper with strong evaluation design innovation). Our paper is stronger than LLaPA (cleaner evaluation, fewer fundamental issues) but weaker than Bioactivity (issues are more damaging to core claims).

**Final Score: 6.0**. The "two orders of magnitude" overstatement and missing ablation for the contact-map mechanism pull the score down. The prospective evaluation design and comprehensive re-ranking analysis are genuine strengths.

## Summary
This paper introduces PPI candidate ranking — prioritizing novel protein-protein interaction candidates for experimental validation by leveraging known interaction partners. The method extracts active residue regions from predicted inter-protein contact maps (D-SCRIPT/Topsy-Turvy) of known partners, then ranks candidates by embedding cosine similarity restricted to those regions. A re-ranking stage integrates interaction scores, structural plausibility (SpeedPPI/pDockQ), semantic overlaps, and LLM-based signals. The evaluation uses a prospective STRING v11→v12 split — an innovative design where v11 interactions serve as retrieval anchors and v12 additions as ground-truth.

## Strengths
- **Prospective STRING v11→v12 evaluation (Section 5.1, Table 1):** Using successive STRING releases to test whether methods can anticipate future experimental discoveries is genuinely innovative. No prior PPI prediction work uses inter-release transitions at this scale, and this directly addresses the paper's core claim about prospective value.
- **Substantial retrieval improvements across two model backbones (Table 1):** D-SCRIPT Recall@10 rises from 0.0124 to 0.2641 (~21×) and Topsy-Turvy Recall@10 rises from negligible to 0.1106, with MRR increasing 4-6× for both. These gains demonstrate generality across architectures and are practically meaningful — for D-SCRIPT, over 13% of top-10 suggestions are true novel partners.
- **Comprehensive pairwise rank-shift analysis across 10 re-ranking signals (Table 2):** The asymmetric matrix presentation systematically quantifies directional complementarity — e.g., PubMedBERT cross-encoder maintains or improves 75.5% of rediscoveries vs. cosine baseline, while pDockQ only manages 47.2%. Lightweight semantic features (TF-IDF, token/keyterm overlap) perform surprisingly competitively (up to ~70%), providing actionable cost-effectiveness guidance.
- **Clean problem formalization and reproducible method (Section 4, Eqs. 1–5):** The mathematical setup — KP(p)/NP(p)/CP(p) definitions, sliding-window cosine similarity over active residue regions (Eq. 3), and max-pooling across known anchors (Eq. 4) — is rigorous and unambiguous.
- **Multi-modal re-ranking spanning five distinct evidence families (Section 4.2):** Sequence-based interaction scores, structure-based pDockQ, ontology/semantic overlaps, bi-encoder LLM embeddings, and a fine-tuned cross-encoder provide genuinely orthogonal biological modalities.
- **Honest acknowledgment of limitations (Section 6):** The paper explicitly notes degradation for proteins with few known partners and that using interpretability as a retrieval mechanism does not make output rankings themselves interpretable.

## Weaknesses

### Fatal
None.

### Major
- **"Two orders of magnitude" claim is an overstatement (lines 25, 279):** The paper states results show "two orders of magnitude" improvement, but the actual numbers in Table 1 tell a different story. For D-SCRIPT (the paper's preferred backbone), the largest improvement is Recall@5 at ~26× and MRR at ~5×. For Topsy-Turvy, one data point (Recall@10: 0.00117→0.1106 ≈ 94.5×) approaches but does not reach 100×, and most improvements are 5-26× — roughly one order of magnitude. This systematic overstatement undermines the credibility of otherwise solid results. The numbers are strong enough to stand without exaggeration.
- **Missing ablation for the contact-map mechanism:** The paper's central methodological claim is that contact-map-guided active-region extraction (Section 4.1) improves ranking. However, no ablation compares this against a simpler baseline that ranks by max cosine similarity between the *full* embeddings of known partners and candidates (without contact-map filtering). Without this ablation, we cannot assess whether the contact-map machinery specifically adds value, or whether gains come primarily from the simpler strategy of using known-partner embeddings as search anchors. The current comparison conflates two factors: (a) using known partners as anchors vs. (b) using contact-map-guided active regions.

### Minor
- **Re-ranking evaluation lacks end-to-end retrieval metrics (Table 2):** The pairwise rank-shift analysis operates within a fixed pool of 2,280 top-10 candidates and reports maintain-or-improve fractions. No Recall@k, Precision@k, or MRR is reported after re-ranking. A reader cannot tell whether, e.g., PubMedBERT's 75.5% maintain-or-improve rate translates into meaningfully better top-k lists.
- **Robustness to noisy KP(p) sets not discussed:** The max-pooling over known partners (Eq. 4) means a candidate with high similarity to any single known partner can rank highly. STRING interactions carry varying confidence levels; one spurious or promiscuous known partner could dominate.
- **LLM data leakage for bi-encoders acknowledged but not controlled:** The paper notes (lines 262-264) that biomedical LLMs may contain latent knowledge of interactions from training data. The cross-encoder uses GroupKFold by protein identity, but bi-encoders have no such protection and no control analysis is provided.
- **Contact-map overfitting concern unexamined:** D-SCRIPT/Topsy-Turvy were trained on STRING v11, so contact maps for known partners are predictions on training data. While the prospective v12 evaluation partially mitigates this (overfit maps would not help predict genuinely novel interactions), no analysis examines whether extracted active regions correspond to genuine biological interfaces.

### Trivial
- The "interpretability" framing is confusing: the paper explicitly states it does "not frame interpretability here as a means to generate explanations for users" (line 21) but uses "interpretability-guided" as the method's name, creating false expectations.
- The total number of proteins |P| and typical candidate set size |CP(p)| are never stated, making it difficult to calibrate retrieval metrics.
- The pDockQ poor-performance explanation — "could be probably justified by the high sensitivity of AlphaFold2 with respect to the seed" (lines 253-254) — is speculative and undersupported.

## Nice-to-Haves
- Add the full-embedding cosine similarity ablation to Table 1 to isolate the contact-map mechanism's contribution.
- Report end-to-end retrieval metrics (Recall@k, Precision@k, MRR) after applying each re-ranking strategy.
- Provide a quantitative breakdown of the "hundreds of hours" runtime.
- Compare against sequence-alignment baselines (e.g., BLAST E-value to known partners) to control for homology-driven signal.

## Removed Points
These points are flagged to be removed, treat them with caution.

- **Harsh Critic — "comparison is fundamentally unbalanced":** REMOVED. The comparison between "Our Approach" (using KP(p)) and baselines (raw probabilities) is between different paradigms intentionally — the paper is upfront about leveraging known partners. The comparison is valid as a demonstration. The missing ablation IS a real concern (kept as Major).
- **Harsh Critic — missing discussion of network-propagation/guilt-by-association methods:** REMOVED per rules (cannot verify existence of missing related works without external sources).
- **Harsh Critic — Bepler & Berger d=6165 without comment:** REMOVED. This is an observation about a well-known encoder, not a weakness of the paper.
- **Harsh Critic — "interpretability" novelty framing overstatement in introduction:** REMOVED. The harsh critic claimed the paper overstates novelty by calling it "introducing the problem" — but introducing a formal problem definition is legitimate contribution language, and the paper cites Borghini et al. as prior work.
- **Harsh Critic — missing cross-encoder results in Section 5:** REMOVED. The PubMedBERT cross-encoder results ARE reported in Table 2 (75.5% maintain-or-improve vs. Cosine); the criticism is factually incorrect.
- **Strength Finder — generic "important problem" / "interesting question":** REMOVED. Generic framing without concrete evidence tied to this paper specifically.

## Novel Insights
The most genuinely novel finding is that lightweight semantic overlap features (TF-IDF, token/keyterm Jaccard) achieve re-ranking performance competitive with much more expensive LLM-based methods (Table 2: KeyTerm overlap improves 69.3% vs. Cosine, comparable to BioBERT at 55.8%). This suggests that for PPI candidate prioritization, curated functional annotations may already capture much of the signal that LLMs extract from biomedical text — an insight with practical implications for cost-aware pipeline design.

## Suggestions
- Correct the "two orders of magnitude" language throughout to reflect actual numbers (e.g., "one order of magnitude" or specific multiplicative factors).
- Add the full-embedding cosine similarity ablation to Table 1. If it performs comparably, the paper's contribution shifts to the overall known-partner anchoring framework (still valuable); if contact maps provide a clear delta, that becomes the strongest evidence for the specific mechanism.
- Report end-to-end retrieval metrics after re-ranking to quantify the practical impact of the re-ranking module.
- State |P| and typical |CP(p)| explicitly in Section 5.1.

---

**Anchor comparison summary:**

| Path | Avg Score | Round | Comparison to paper under review |
|------|-----------|-------|----------------------------------|
| S2WHlhvFGg (Drug-Target DTI) | 3.00 | R1 | Much weaker — theoretical, no real empirical validation |
| IEZjjDX0iC (pLM remote homology) | 3.00 | R1 | Much weaker — limited evaluation, narrow scope |
| 44IKUSdbUD (Gene-gene interaction) | 3.00 | R1 | Much weaker — computational, speculative |
| 1S8ndwxMts (Protein gen metrics) | 3.00 | R1 | Much weaker — survey of metrics, no method |
| itGkF993gz (MAPE-PPI) | 5.67 | R1 | Weaker — less innovative evaluation, unclear efficiency claims |
| jsQPjIaNNh (ProtIR function pred) | 5.25 | R1 | Weaker — missing baselines, unclear datasets |
| eh1fL0zw8o (LLaPA) | 6.00 | R1/R2 | Comparable score — more fundamental issues (unfair comparison, data leakage) but more ambitious method |
| 760br3YEtY (PEEP) | 5.60 | R2 | Weaker — narrower scope (enzyme promiscuity) |
| S8gbnkCgxZ (Bioactivity Prediction) | 7.00 | R2 | Stronger — benchmark dataset contribution, cleaner evaluation |
| sTYuRVrdK3 (ProteinWorkshop) | 6.25 | R2 | Similar score — benchmark paper, different domain |
| uQnvYP7yX9 (ReNovo) | 6.50 | R2 | Slightly stronger — cleaner task definition, retrieval-based de novo sequencing |
| ua5MHdsbck (Data Distillation) | 7.00 | R2 | Stronger — more focused contribution, cleaner evaluation |

**Final Score: 6.0** — positioned above LLaPA (6.00, which had more fundamental evaluation issues) and below Bioactivity Prediction (7.00) and ReNovo (6.50). Comparable to ProteinWorkshop (6.25) but with more significant credibility issues (overstated claims) and methodological gaps (missing ablation) that pull it down.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Reject</decision>